Showing 4061-4070 of 9943 results for "".
- European Commission Approves UCB's BIMZELX for Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/european-commission-approves-ucbs-bimzelx-for-adults-with-moderate-to-severe-plaque-psoriasis/2460895/The European Commission (EC) has granted marketing authorization for UCB's bimekizumab (Bimzelx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimekizumab is the first approved treatment in the European Union (EU) for moderate
- L'Oréal's SkinCeuticals Taps New GMhttps://practicaldermatology.com/news/loreals-skinceuticals-taps-new-gm/2460621/Stephanie Kramer is L'Oréal's SkinCeuticals new General Manager. Kramer was Global Senior Vice President of Marketing, Product Innovation and Retail at SkinCeuticals. Prior to joining SkinCeuticals in 2019, Kramer served as Vice President of Global Marketi
- MD Survey: Telehealth Booming, Prescribing Habits Changing During Pandemichttps://practicaldermatology.com/news/md-survey-telehealth-booming-prescribing-habits-changing-during-pandemic/2460360/More than four-fifths of physicians saw fewer patients in late March, averaging 40 patients per week vs. 103 per week prior to March 2020, according to a new survey of 500 U.S physicians by AbelsonTaylor, a health and wellness marketing agency. What’s more, three-quarters of physi
- Wontech Scores FDA Nod for Sandro Dual Laserhttps://practicaldermatology.com/news/wontech-scores-fda-nod-for-sandro-dual-laser/2460333/The U.S. Food and Drug Administration granted 510 (K) marketing clearance to Wontech’s Sandro Dual, a hybrid Nd:YAG & Alexandrite laser device. In the hybrid mode, by irradiating a short time difference between two wavelengths of 755nm and 1064nm, the laser accurately hits its
- Melanoma Rates Drop Sharply Among Teens, Young Adultshttps://practicaldermatology.com/news/melanoma-rates-drop-sharply-among-teens-young-adults/2460217/Cases of melanoma among U.S. adolescents and young adults declined markedly from 2006 to 2015 - even as the skin cancer's incidence continued to increase among older adults and the general population during the span, new research in JAMA Dermatology shows. The finding,
- Joanna Zucker is New CEO at PCA Skinhttps://practicaldermatology.com/news/joanna-zucker-is-new-ceo-at-pca-skin/2460071/With more than 25 years of experience in Consumer Packaged Goods and Retail, Joanna Zucker is assuming the role of Chief Executive Officer for PCA SKIN, part of Colgate-Palmolive's professional skin care portfolio. Ms. Zucker previously served in senior management and marketing
- FDA Green Lights First Spray-on-Skin Product for Burnshttps://practicaldermatology.com/news/fda-green-lights-first-spray-on-skin-product-for-burns/2457598/The US Food and Drug Administration granted premarket approval to Avita Medical’s Recell, a spray-on-skin that treats second- and third-degree burns in patients aged older than 18 years. The U.S. market launch for the Recell Autologous Cell Harvesting Device (RECELL® System) is
- Ekwa Marketing Launches Affiliate Program, Offers Residual Income Opportunity for Medical Associationshttps://practicaldermatology.com/news/ewa-marketing-launches-affiliate-program-offers-residual-income-opportunity-for-medical-associations/2457622/Ekwa Marketing has launched its unique Ekwa Affiliate Program. Medical associations can simply place an online link to Ekwa’s innovative digital marketing products for doctors on their website and social media networks, and start receiving a passive i
- RealSelf Names Tanja Omeze Chief Marketing Officerhttps://practicaldermatology.com/news/realself-names-tanja-omeze-chief-marketing-officer/2457808/Ms. Tanja Omeze is RealSelf’s first ever chief marketing officer (CMO). As CMO, Ms. Omeze leads global marketing to increase awareness, engagement and connections among and between consumers and medical aesthetic professionals. Ms. Omez
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep